Proactive Investors - Run By Investors For Investors

Kazia Therapeutics developing unique drug to battle brain cancer

Kazia Therapeutics Limited (NASDAQ:KZIA)(ASX:KZA) CEO James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The Sydney, Australia based oncology-focused biotechnology company develops anti-cancer drugs; its pipeline includes two clinical-stage drug development candidates. Its lead candidate is GDC-0084, which has entered a phase II clinical trial in March 2018, with initial data expected in early calendar 2019.

Meet ICOx Innovations, Zynerba Pharmaceuticals, Pressure BioSciences Inc. and Alchemist Inc at our event, New York , 30 January 2019. Register here »
View full KZA profile View Profile

Kazia Therapeutics Ltd Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use